Notably, GLP-1 analogs, SGLT2 inhibitors, and DPP-4 inhibitors have been explored in feline and canine models, potentially providing translational insights applicable to human diabetes therapy [61,132]. This evidence concerns the gene SLC5A2 and diabetes mellitus.